Inhibrx Biosciences reports $1.9B net income in Q2 2024 after separation from former parent

Inhibrx Biosciences, Inc.

2024-Q2 EPS reported $122.75 revenue$100,000

Net income of $1.9 billion for Q2 2024, compared to net loss of $47.1 million in Q2 2023
Cash and cash equivalents $226.9M as of June 30, 2024, down from $255.4M at May 30 separation
Separation from Inhibrx, Inc. completed May 30: INBRX-101 transferred to Sanofi for ~$2.2B
Stockholders received $30 cash per share, one $5 CVR, and one Inhibrx Biosciences share per four former parent shares

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.